Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The impact of intratumoral heterogeneity (ITH) and the resultant neoantigen landscape on T cell immunity are poorly understood. ITH is a widely recognized feature of solid tumors and poses distinct challenges related to the development of effective therapeutic strategies, including cancer neoantigen vaccines. Here, we performed deep targeted DNA sequencing of multiple metastases from melanoma patients and observed ubiquitous sharing of clonal and subclonal single nucleotide variants (SNVs) encoding putative HLA class I-restricted neoantigen epitopes. However, spontaneous antitumor CD8+ T cell immunity in peripheral blood and tumors was restricted to a few clonal neoantigens featuring an oligo-/monoclonal T cell-receptor (TCR) repertoire. Moreover, in various tumors of the 4 patients examined, no neoantigen-specific TCR clonotypes were identified despite clonal neoantigen expression. Mature dendritic cell (mDC) vaccination with tumor-encoded amino acid-substituted (AAS) peptides revealed diverse neoantigen-specific CD8+ T responses, each composed of multiple TCR clonotypes. Isolation of T cell clones by limiting dilution from tumor-infiltrating lymphocytes (TILs) permitted functional validation regarding neoantigen specificity. Gene transfer of TCRαβ heterodimers specific for clonal neoantigens confirmed correct TCR clonotype assignments based on high-throughput TCRBV CDR3 sequencing. Our findings implicate immunological ignorance of clonal neoantigens as the basis for ineffective T cell immunity to melanoma and support the concept that therapeutic vaccination, as an adjunct to checkpoint inhibitor treatment, is required to increase the breadth and diversity of neoantigen-specific CD8+ T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Therapeutic vaccination and related interventions that facilitate antigen cross-presentation in secondary lymphoid organs will likely be required to increase the breadth, diversity, and frequency of neoantigen-specific CD8+ T cells as an adjunct to checkpoint inhibitor treatment for cancer (32).”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · cited 1×
“In support of this proposal, personalized cancer vaccine studies from several investigative teams report the induction of mutant peptide-specific CD8+ and CD4+ T cells directed against ubiquitous clonal neoantigens for melanoma (10, 33, 34), glioblastoma (35, 36), and ovarian carcinoma (37).”
BackgroundTumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“This finding agrees with published results from experimental tumor models that indicate that the host immune response is restricted to a small fraction of candidate neoantigens (26, 27).”
ResultSelf-citationA dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Self-citationPredicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186 · cited 1×
“This finding agrees with published results from experimental tumor models that indicate that the host immune response is restricted to a small fraction of candidate neoantigens (26, 27).”
ResultActively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Cited by
Cancer immunotherapy: Pros, cons and beyond
Tan, S., Li, D., & Zhu, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 688
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Gainor, J. F., Patel, M. R., Weber, J. S., Gutierrez, M., Bauman, J. E., Clarke, J. M., Julian, R., Scott, A. J., Geiger, J. L., Kirtane, K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0158 · Cited by 124
Bear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24562-2 · Cited by 113
Self-citationFacts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations
Linette, G. P., Bear, A. S., & Carreno, B. M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1212 · Cited by 14
“Importantly, the majority of these neoantigens are encoded by unique (or private) passenger mutations displaying intratumor heterogeneity (ITH), de fi ned as present in a fraction, not the totally, of tumor cells, and presumablyplayingalimitedroleindiseasepathogenesis(16,17).”
BackgroundSelf-citation
Metadata
- Authors
- Linette, G. P., Becker-Hapak, M., Skidmore, Z. L., Baroja, M. L., Xu, C., Hundal, J., Spencer, D. H., Fu, W., Cummins, C., Robnett, M., Kaabinejadian, S., Hildebrand, W. H., Magrini, V., Demeter, R., Krupnick, A. S., Griffith, O. L., Griffith, M., Mardis, E. R., & Carreno, B. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2019-11-04
- Volume
- 116
- Issue
- 47
- Pages
- 23662-23670
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2987616600
- Cited by
- 62
- References
- 10
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. https://app.cochat.ai/papers/10.1073/pnas.1906026116
- The paper
- Linette, G. P., Becker-Hapak, M., Skidmore, Z. L., Baroja, M. L., Xu, C., Hundal, J., Spencer, D. H., Fu, W., Cummins, C., Robnett, M., Kaabinejadian, S., Hildebrand, W. H., Magrini, V., Demeter, R., Krupnick, A. S., Griffith, O. L., Griffith, M., Mardis, E. R., & Carreno, B. M. (2019). Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1906026116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.